COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects

NCT00654485 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

940

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Syndrome

Interventions

DRUG: Rosuvastatin
DRUG: Atorvastatin

Sponsor

AstraZeneca